



13

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: A61K 39/395, A61P 37/06, C07K 14/55, C07K 16/28, C07K 19/00	A1	(11) International Publication Number: WO 00/74718 (43) International Publication Date: 14 December 2000 (14.12.2000)
(21) International Application Number: PCT/US00/15780		Published
(22) International Filing Date: 09 June 2000 (09.06.2000)		
(30) Priority Data: 60/138,284 09 June 1999 (09.06.1999) US		
(60) Parent Application or Grant IMMUNOMEDICS, INC. [/]; O. GOLDENBERG, David, M. [/]; O. HANSEN, Hans, J. [/]; O. GOLDENBERG, David, M. [/]; O. HANSEN, Hans, J. [/]; O. SAXE, Bernhard, D. ; O.		
(54) Title: IMMUNOTHERAPY OF AUTOIMMUNE DISORDERS USING ANTIBODIES WHICH TARGET B-CELLS (54) Titre: IMMUNOTHERAPIE DE TROUBLES AUTO-IMMUNS A L'AIDE D'ANTICORPS CIBLANT LES CELLULES B		
(57) Abstract Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies.		
(57) Abrégé L'invention concerne des anticorps se liant à un antigène de cellules B et offrant un moyen efficace de traiter des troubles auto-immuns. Des anticorps et des fragments, qui peuvent être conjugués ou nus, sont utilisés isolément ou dans des thérapies multimodales. Les anticorps peuvent être des anticorps bispécifiques pouvant être produits par recombinaison en tant que protéines hybrides ou en tant qu'anticorps hybrides polypécifiques.		

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 December 2000 (14.12.2000)

PCT

(10) International Publication Number
WO 00/74718 A1

(51) International Patent Classification⁷: A61K 39/395, C07K 16/28, 19/00, A61P 37/06 // C07K 14/55 (74) Agent: SAXE, Bernhard, D.; Foley & Lardner, 3000 K Street, NW, Washington, DC 20007-5109 (US).

(21) International Application Number: PCT/US00/15780

(22) International Filing Date: 9 June 2000 (09.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/138,284 9 June 1999 (09.06.1999) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/138,284 (CIP)
Filed on 9 June 1999 (09.06.1999)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 00/74718 A1

(54) Title: IMMUNOTHERAPY OF AUTOIMMUNE DISORDERS USING ANTIBODIES WHICH TARGET B-CELLS

(57) Abstract: Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies.

Description

5

10

15

20

25

30

35

40

45

50

55

5

10

5

**IMMUNOTHERAPY OF AUTOIMMUNE DISORDERS
USING ANTIBODIES WHICH TARGET B-CELLS**

30

25

15

20

25

30

35

Field of the Invention

10

40

45

50

The present invention relates to immunotherapeutic methods for treating autoimmune disorders. In particular, this invention is directed to methods for treating autoimmune disorders by administering antibodies that bind to a B-cell antigen, such as the CD22, CD20, CD19, and CD74 or HLA-DR antigen. The antibodies are administered alone or in combination, and may be naked or conjugated to a drug, toxin or therapeutic radioisotope. Bispecific antibody fusion proteins which bind to the B-cell antigens can be used according to the present invention, including hybrid antibodies which bind to more than one B-cell antigen. The present invention also is directed to multimodal therapeutic methods in which the antibody administration is supplemented by administration of other therapeutic modalities.

Background

25

30

35

40

45

50

Antibodies against the CD20 antigen have been investigated for the therapy of B-cell lymphomas. For example, a chimeric anti-CD20 antibody, designated as "IDE-C2B8," has activity against B-cell lymphomas when provided as unconjugated antibodies at repeated injections of doses exceeding 500 mg per injection. Maloney *et al.*, *Blood* 84:2457 (1994); Longo, *Curr. Opin. Oncol.* 8:353 (1996). About 50 percent of non-Hodgkin's patients, having the low-grade indolent form, treated with this regimen showed responses. Therapeutic responses have also been obtained using ¹³¹I-labeled B1 anti-CD-20 murine monoclonal antibody when provided as repeated doses exceeding 600 mg per injection. Kaminski *et al.*, *N.*

55

Engl. J. Med. 329:459 (1993); Press *et al.*, *N. Engl. J. Med.* 329:1219 (1993);
Press *et al.*, *Lancet* 346:336 (1995). However, these antibodies, whether provided
as unconjugated forms or radiolabeled forms, have shown only modest activity in
patients with the more prevalent and lethal form of B-cell lymphoma, the
intermediate or aggressive type.

15 Autoimmune diseases are a class of diseases associated with a B-cell disorder. Examples include immune-mediated thrombocytopenias, such as acute idiopathic thrombocytopenic purpura and chronic idiopathic thrombocytopenic purpura, myasthenia gravis, lupus nephritis, lupus erythematosus, and rheumatoid 10 arthritis. The most common treatments are corticosteroids and cytotoxic drugs, which can be very toxic. These drugs also suppress the entire immune system, can result in serious infection, and have adverse affects on the liver and kidneys. Other 20 therapeutics that have been used to treat Class III autoimmune diseases to date have been directed against T-cells and macrophages. A need remains for more effective 25 methods of treating autoimmune diseases, particularly Class III autoimmune diseases.

SUMMARY OF THE INVENTION

20 Accordingly, it is an object of the present invention to provide a method for
treating autoimmune diseases using antibody to a B-cell antigen.

35 It is another object of the invention is to use comparatively low doses of a
naked antibody to a B-cell antigen, preferably to CD22 antigen, or a combination of
naked antibodies to a CD22 antigen and another B-cell antigen, preferably CD20
12 25 and/or CD74.

Yet another object of the invention is to use a combination of one or more naked antibodies to B-cell antigens and/or antibodies to B-cell antigens which are conjugated to drugs, toxins or therapeutic radioisotopes.

45 It is a further object of this invention to provide multimodal methods for
30 treatment of autoimmune diseases in which a naked or conjugated antibody to a B-
cell antigen is supplemented with the administration of other therapeutic modalities,
50 such as those directed against T-cells, plasma cells and macrophages.

5 These and other objects are achieved, in accordance with one embodiment of
the present invention, by the provision of a method of treating an autoimmune
disease, comprising the step of administering to a subject having an autoimmune
disease an antibody to a B-cell antigen and a pharmaceutically acceptable carrier.

10 5 Other objects, features and advantages of the present invention will become
apparent from the following detailed description. It should be understood, however,
that the detailed description and the specific examples, while indicating preferred
embodiments of the invention, are given by way of illustration only, since various
15 changes and modifications within the spirit and scope of the invention will become
apparent to those skilled in the art from this detailed description.

20 **DETAILED DESCRIPTION**

25 **1. Overview**

15 15 B-cell clones that bear autoantibody Ig-receptors are present in normal
individuals. Autoimmunity results when these B-cells become overactive, and
mature to plasma cells that secrete autoantibody. In accordance with the present
30 invention, autoimmune disorders can be treated by administering an antibody that
binds to a B-cell antigen, such as the CD22, CD20, CD19, and CD74 or HLA-DR
20 antigen. In one embodiment, comparatively low doses of an entire, naked antibody
or combination of entire, naked antibodies are used. In other embodiments,
35 conjugates of such antibodies with drugs, toxins or therapeutic radioisotopes are
useful. Bispecific antibody fusion proteins which bind to the B-cell antigens can be
used according to the present invention, including hybrid antibodies which bind to
40 more than one B-cell antigen. Preferably the bispecific and hybrid antibodies
additionally target a T-cell, plasma cell or macrophage antigen. The present
invention also is directed to multimodal therapeutic methods in which the antibody
administration is supplemented by administration of other therapeutic modalities.

45

50

55

5 **2. Definitions**

In the description that follows, and in documents incorporated by reference, a number of terms are used extensively. The following definitions are provided to facilitate understanding of the invention.

10 5 A **structural gene** is a DNA sequence that is transcribed into messenger RNA (mRNA) which is then translated into a sequence of amino acids characteristic of a specific polypeptide.

15 15 A **promoter** is a DNA sequence that directs the transcription of a structural gene. Typically, a promoter is located in the 5' region of a gene, proximal to the 10 transcriptional start site of a structural gene. If a promoter is an inducible promoter, then the rate of transcription increases in response to an inducing agent. In contrast, 20 the rate of transcription is not regulated by an inducing agent when the promoter is a constitutive promoter.

25 25 An **isolated DNA molecule** is a fragment of DNA that is not integrated in the genomic DNA of an organism. For example, a cloned antibody gene is a DNA fragment that has been separated from the genomic DNA of a mammalian cell. Another example of an isolated DNA molecule is a chemically synthesized DNA 30 molecule that is not integrated in the genomic DNA of an organism.

35 20 An **enhancer** is a DNA regulatory element that can increase the efficiency of transcription, regardless of the distance or orientation of the enhancer relative to the start site of transcription.

40 25 **Complementary DNA** (cDNA) is a single-stranded DNA molecule that is formed from a mRNA template by the enzyme reverse transcriptase. Typically, a primer complementary to portions of mRNA is employed for the initiation of 45 reverse transcription. Those skilled in the art also use the term "cDNA" to refer to a double-stranded DNA molecule consisting of such a single-stranded DNA molecule and its complementary DNA strand.

45 30 The term **expression** refers to the biosynthesis of a gene product. For example, in the case of a structural gene, expression involves transcription of the structural gene into mRNA and the translation of mRNA into one or more polypeptides.

50

5 A cloning vector is a DNA molecule, such as a plasmid, cosmid, or
bacteriophage that has the capability of replicating autonomously in a host cell.
Cloning vectors typically contain one or a small number of restriction endonuclease
recognition sites at which foreign DNA sequences can be inserted in a determinable
10 5 fashion without loss of an essential biological function of the vector, as well as a
marker gene that is suitable for use in the identification and selection of cells
transformed with the cloning vector. Marker genes typically include genes that
15 15 provide tetracycline resistance or ampicillin resistance.

20 20 An expression vector is a DNA molecule comprising a gene that is
expressed in a host cell. Typically, gene expression is placed under the control of
certain regulatory elements, including constitutive or inducible promoters, tissue-
specific regulatory elements, and enhancers. Such a gene is said to be "operably
linked to" the regulatory elements.

25 25 A recombinant host may be any prokaryotic or eukaryotic cell that contains
either a cloning vector or expression vector. This term also includes those
prokaryotic or eukaryotic cells that have been genetically engineered to contain the
cloned gene(s) in the chromosome or genome of the host cell.

30 30 As used herein, antibody encompasses naked antibodies and conjugated
antibodies and antibody fragments, which may be monospecific or multispecific. It
20 20 includes both polyclonal and monoclonal antibodies, as well as certain recombinant
antibodies, such as chimeric and humanized antibodies and fusion proteins.

35 35 A chimeric antibody is a recombinant protein that contains the variable
domains and complementary determining regions derived from a rodent antibody,
while the remainder of the antibody molecule is derived from a human antibody.

40 40 Humanized antibodies are recombinant proteins in which murine
complementarity determining regions of a monoclonal antibody have been
transferred from heavy and light variable chains of the murine immunoglobulin into
a human variable domain.

45 45 Human antibodies are antibodies that either are isolated from humans and
then grown out in culture or are made using animals whose immune systems have
30 30 been altered so that they respond to antigen stimulation by producing human
antibodies.

5 As used herein, a therapeutic agent is a molecule or atom, which is conjugated to an antibody moiety to produce a conjugate which is useful for therapy. Examples of therapeutic agents include drugs, toxins, enzymes, hormones, cytokines, immunomodulators, boron compounds and therapeutic radioisotopes.

10 5 Preferred therapeutic radioisotopes include beta, alpha, and Auger emitters, with a kev range of 80-500 kev. Exemplary therapeutic radioisotopes include ¹⁹⁸Au, ³²P, ¹²⁵I, ¹³¹I, ⁹⁰Y, ¹⁸⁶Re, ¹⁸⁸Re, ⁶⁷Cu, and ²¹¹At.

15 10 A naked antibody is an entire antibody which is not conjugated with a therapeutic agent. Naked antibodies include both polyclonal and monoclonal antibodies, as well as certain recombinant antibodies, such as chimeric and humanized antibodies.

20 20 A conjugated antibody is an antibody or antibody fragment that is conjugated to a therapeutic agent.

25 15 A multispecific antibody is an antibody which can bind simultaneously to at least two targets which are of different structure, e.g., two different antigens, two different epitopes on the same antigen, or a hapten and/or an antigen or epitope. One specificity would be for a B-cell antigen or epitope.

30 30 A bispecific antibody is an antibody which can bind simultaneously to two targets which are of different structure. Bispecific antibodies (bsAb) and bispecific antibody fragments (bsFab) have at least one arm that specifically binds to a B-cell antigen or epitope and at least one other arm that specifically binds a targetable conjugate.

40 45 A fusion protein is a recombinantly produced antigen-binding molecule in which two or more different single-chain antibody or antibody fragment segments with the same or different specificities are linked. A variety of bispecific fusion proteins can be produced using molecular engineering. In one form, the bispecific fusion protein is monovalent, consisting of, for example, a scFv with a single binding site for one antigen and a Fab fragment with a single binding site for a second antigen. In another form, the bispecific fusion protein is divalent, consisting of, for example, an IgG with two binding sites for one antigen and two scFv with two binding sites for a second antigen.

50

5 **3. Production of Monoclonal Antibodies, Humanized Antibodies, Primate
Antibodies and Human Antibodies**

10 Anti-CD20, anti-CD22, anti-CD19, and anti-CD74 antibodies are known generally to those of skill in the art. See, for example, Ghetie *et al.*, *Cancer Res.*

15 48:2610 (1988); Hekman *et al.*, *Cancer Immunol. Immunother.* 32:364 (1991);

20 Kaminski *et al.*, *N. Engl. J. Med.* 329:459 (1993); Press *et al.*, *N. Engl. J. Med.*

25 329:1219 (1993); Maloney *et al.*, *Blood* 84:2457 (1994); Press *et al.*, *Lancet*

30 346:336 (1995); Longo, *Curr. Opin. Oncol.* 8:353 (1996). More particularly,

35 rodent monoclonal antibodies to CD22, CD20, CD19, or CD74 antigens can be obtained by methods known to those skilled in the art. See generally, for example,

40 Kohler and Milstein, *Nature* 256:495 (1975), and Coligan *et al.* (eds.), CURRENT

45 PROTOCOLS IN IMMUNOLOGY, VOL. 1, pages 2.5.1-2.6.7 (John Wiley &

50 Sons 1991) ["Coligan"]. Briefly, monoclonal antibodies can be obtained by

55 injecting mice with a composition comprising the antigen, verifying the presence of

60 antibody production by removing a serum sample, removing the spleen to obtain B-

65 lymphocytes, fusing the B-lymphocytes with myeloma cells to produce hybridomas,

70 cloning the hybridomas, selecting positive clones which produce antibodies to the

75 antigen that was injected, culturing the clones that produce antibodies to the antigen,

80 and isolating the antibodies from the hybridoma cultures.

85 Monoclonal antibodies can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include

90 affinity chromatography with Protein-A Sepharose, size-exclusion chromatography,

95 and ion-exchange chromatography. See, for example, Coligan at pages 2.7.1-2.7.12

100 and pages 2.9.1-2.9.3. Also, see Baines *et al.*, "Purification of Immunoglobulin G

105 (IgG)," in METHODS IN MOLECULAR BIOLOGY, VOL. 10, pages 79-104 (The

110 Humana Press, Inc. 1992).

115 Suitable amounts of well-characterized antigen for production of antibodies

120 can be obtained using standard techniques. As an example, CD22 can be

125 immunoprecipitated from B-lymphocyte protein using the deposited antibodies

130 described by Tedder *et al.*, U.S. patent No. 5,484,892 (1996).

135 Alternatively, CD22, CD20, CD19, or CD74 antigen proteins can be obtained from transfected cultured cells that overproduce the antigen of interest.

5 Expression vectors that comprise DNA molecules encoding each of these proteins
can be constructed using published nucleotide sequences. See, for example, Wilson
et al., *J. Exp. Med.* 173:137 (1991); Wilson *et al.*, *J. Immunol.* 150:5013 (1993).
10 As an illustration, DNA molecules encoding CD22 can be obtained by synthesizing
DNA molecules using mutually priming long oligonucleotides. See, for example,
Ausubel *et al.*, (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY,
15 pages 8.2.8 to 8.2.13 (1990) ["Ausubel"]. Also, see Wosnick *et al.*, *Gene* 60:115
(1987); and Ausubel *et al.* (eds.), SHORT PROTOCOLS IN MOLECULAR
BIOLOGY, 3rd Edition, pages 8-8 to 8-9 (John Wiley & Sons, Inc. 1995).
20 Established techniques using the polymerase chain reaction provide the ability to
synthesize genes as large as 1.8 kilobases in length. Adang *et al.*, *Plant Molec.*
Biol. 21:1131 (1993); Bambot *et al.*, *PCR Methods and Applications* 2:266 (1993);
Dillon *et al.*, "Use of the Polymerase Chain Reaction for the Rapid Construction of
25 Synthetic Genes," in METHODS IN MOLECULAR BIOLOGY, Vol. 15: PCR
PROTOCOLS: CURRENT METHODS AND APPLICATIONS, White (ed.), pages
263-268, (Humana Press, Inc. 1993).

In a variation of this approach, monoclonal antibody can be obtained by
30 fusing myeloma cells with spleen cells from mice immunized with a murine pre-B
cell line stably transfected with cDNA which encodes the antigen of interest. See
20 Tedder *et al.*, U.S. patent No. 5,484,892 (1996).

One example of a suitable murine anti-CD22 monoclonal antibody is the LL2
35 (formerly EPB-2) monoclonal antibody, which was produced against human Raji
cells derived from a Burkitt lymphoma. Pawlak-Byczkowska *et al.*, *Cancer Res.*
49:4568 (1989). This monoclonal antibody has an IgG_{2a} isotype, and the antibody
40 is rapidly internalized into lymphoma cells. Shih *et al.*, *Int. J. Cancer* 56:538
(1994). Immunostaining and *in vivo* radioimmunodetection studies have
demonstrated the excellent sensitivity of LL2 in detecting B-cell lymphomas.
Pawlak-Byczkowska *et al.*, *Cancer Res.* 49:4568 (1989); Murthy *et al.*, *Eur. J.*
45 *Nucl. Med.* 19:394 (1992). Moreover, ^{99m}Tc-labeled LL2-Fab' fragments have been
30 shown to be useful in following upstaging of B-cell lymphomas, while ¹³¹I-labeled
intact LL2 and labeled LL2 F(ab')₂ fragments have been used to target lymphoma
sites and to induce therapeutic responses. Murthy *et al.*, *Eur. J. Nucl. Med.* 19:394

5 (1992); Mills *et al.*, *Proc. Am. Assoc. Cancer Res.* 34:479 (1993) [Abstract 2857];
Baum *et al.*, *Cancer* 73 (Suppl. 3):896 (1994); Goldenberg *et al.*, *J. Clin. Oncol.*
9:548 (1991). Furthermore, Fab' LL2 fragments conjugated with a derivative of
10 *Pseudomonas* exotoxin has been shown to induce complete remissions for
measurable human lymphoma xenografts growing in nude mice. Kcritman *et al.*,
Cancer Res. 53:819 (1993). An example of an anti-CD74 antibody is the LL1
antibody.

15 In an additional embodiment, an antibody of the present invention is a
chimeric antibody in which the variable regions of a human antibody have been
10 replaced by the variable regions of a rodent anti-CD22 antibody. The advantages of
chimeric antibodies include decreased immunogenicity and increased *in vivo*
20 stability.

25 Techniques for constructing chimeric antibodies are well known to those of
skill in the art. As an example, Leung *et al.*, *Hybridoma* 13:469 (1994), describe
15 how they produced an LL2 chimera by combining DNA sequences encoding the V_k
and V_H domains of LL2 monoclonal antibody with respective human κ and IgG₁
constant region domains. This publication also provides the nucleotide sequences of
30 the LL2 light and heavy chain variable regions, V_k and V_H, respectively.

35 In another embodiment, an antibody of the present invention is a subhuman
20 primate antibody. General techniques for raising therapeutically useful antibodies in
baboons may be found, for example, in Goldenberg *et al.*, international patent
35 publication No. WO 91/11465 (1991), and in Losman *et al.*, *Int. J. Cancer* 46: 310
(1990).

40 In yet another embodiment, an antibody of the present invention is a
25 "humanized" monoclonal antibody. That is, mouse complementarity determining
regions are transferred from heavy and light variable chains of the mouse
immunoglobulin into a human variable domain, followed by the replacement of
45 some human residues in the framework regions of their murine counterparts.
Humanized monoclonal antibodies in accordance with this invention are suitable for
30 use in therapeutic methods. General techniques for cloning murine immunoglobulin
variable domains are described, for example, by the publication of Orlandi *et al.*,
Proc. Nat'l Acad. Sci. USA 86: 3833 (1989). Techniques for producing humanized
50

5 monoclonal antibodies are described, for example, by Jones *et al.*, *Nature* 321:522
10 (1986), Riechmann *et al.*, *Nature* 332:323 (1988), Verhoeyen *et al.*, *Science*
15 239:1534 (1988), Carter *et al.*, *Proc. Nat'l Acad. Sci. USA* 89:4285 (1992),
20 Sandhu, *Crit. Rev. Biotech.* 12:437 (1992), and Singer *et al.*, *J. Immun.* 150:2844
25 (1993). The publication of Leung *et al.*, *Mol. Immunol.* 32:1413 (1995), describes
the construction of humanized LL2 antibody.

15 In another embodiment, an antibody of the present invention is a human
20 monoclonal antibody. Such antibodies are obtained from transgenic mice that have
been "engineered" to produce specific human antibodies in response to antigenic
challenge. In this technique, elements of the human heavy and light chain locus are
25 introduced into strains of mice derived from embryonic stem cell lines that contain
targeted disruptions of the endogenous heavy chain and light chain loci. The
transgenic mice can synthesize human antibodies specific for human antigens, and
the mice can be used to produce human antibody-secreting hybridomas. Methods
30 for obtaining human antibodies from transgenic mice are described by Green *et al.*,
Nature Genet. 7:13 (1994), Lonberg *et al.*, *Nature* 368:856 (1994), and Taylor *et*
al., *Int. Immun.* 6:579 (1994).

35 **4. Production of bispecific antibodies**

20 The present invention also may employ a bispecific antibody (bsAb) or
30 antibody fragment (bsFab) having at least one arm that specifically binds to a B-cell
antigen and at least one other arm that specifically binds a targetable conjugate. The
targetable conjugate comprises a carrier portion which comprises or bears at least
one epitope recognized by at least one arm of the bispecific antibody or antibody
35 fragment. In a preferred embodiment, the epitope is a hapten. In an alternative
40 embodiment, the epitope is a part of the carrier. Examples of recognizable haptens
include, but are not limited to, chelators, such as DTPA, fluorescein isothiocyanate,
vitamin B-12 and other moieties to which specific antibodies can be raised. The
carrier portion also may be conjugated to a variety of agents. Examples of
45 conjugated agents include, but are not limited to, metal chelate complexes, drugs,
50 toxins and other effector molecules, such as cytokines, lymphokines, chemokines,
immunomodulators, radiosensitizers, asparaginase, carboranes and radioactive

halogens. Additionally, enzymes useful for activating a prodrug or increasing the target-specific toxicity of a drug can be conjugated to the carrier. Thus, the use of bispecific antibodies and fragments which have at least one arm that specifically binds a targetable conjugate allows a variety of therapeutic and diagnostic applications to be performed without raising new bsAb for each application.

The present invention encompasses antibodies and antibody fragments. The antibody fragments are antigen binding portions of an antibody, such as F(ab')2, F(ab')2, Fab', Fab, and the like. The antibody fragments bind to the same antigen that is recognized by the intact antibody. For example, an anti-CD22 monoclonal antibody fragment binds to an epitope of CD22. The bsAb of the present invention include, but are not limited to, IgG x IgG, IgG x F(ab')2, IgG x Fab', IgG x scFv, F(ab')2 x F(ab')2, Fab' x F(ab')2, Fab' x Fab', Fab' x scFv and scFv x scFv bsmabs. Also, species such as scFv x IgG x scFv and Fab' x IgG x Fab', scFv x F(ab')2 x scFv and Fab' x F(ab')2 x Fab' are included.

25 15 The term "antibody fragment" also includes any synthetic or genetically
 engineered protein that acts like an antibody by binding to a specific antigen to form
 a complex. For example, antibody fragments include isolated fragments, "Fv"
 fragments, consisting of the variable regions of the heavy and light chains,
 recombinant single chain polypeptide molecules in which light and heavy chain
 variable regions are connected by a peptide linker ("sFv proteins"), and minimal
 recognition units consisting of the amino acid residues that mimic the hypervariable
 region.

30

35

5. Production of fusion proteins

Another method for producing bsAbs is to engineer recombinant fusion proteins linking two or more different single-chain antibody or antibody fragment segments with the needed dual specificities. See, e.g., Coloma *et al.*, *Nature Biotech.* 15:159-163, 1997. A variety of bispecific fusion proteins can be produced using molecular engineering. In one form, the bispecific fusion protein is monovalent, consisting of, for example, a scFv with a single binding site for one antigen and a Fab fragment with a single binding site for a second antigen. In another form, the bispecific fusion protein is divalent, consisting of, for example, an

5 IgG with two binding sites for one antigen and two scFv with two binding sites for a second antigen.

10 Functional bispecific single-chain antibodies (bscAb), also called diabodies, can be produced in mammalian cells using recombinant methods. See, e.g., Mack
5 et al., Proc. Natl. Acad. Sci., 92: 7021-7025, 1995. For example, bscAb are produced by joining two single-chain Fv fragments via a glycine-serine linker using recombinant methods. The V light-chain (VL) and V heavy-chain (VH) domains of two antibodies of interest are isolated using standard PCR methods. The VL and VH
15 cDNA's obtained from each hybridoma are then joined to form a single-chain fragment in a two-step fusion PCR. The first PCR step introduces the (Gly4-Ser1)3 linker, and the second step joins the VL and VH amplicons. Each single chain molecule is then cloned into a bacterial expression vector. Following amplification,
20 one of the single-chain molecules is excised and sub-cloned into the other vector, containing the second single-chain molecule of interest. The resulting bscAb
25 fragment is subcloned into an eukaryotic expression vector. Functional protein expression can be obtained by transfecting the vector into chinese hamster ovary cells. Recombinant methods can be used to produce a variety of fusion proteins.

30 **6. Coupling of Antibodies to Lipid Emulsions**

20 Long-circulating sub-micron lipid emulsions, stabilized with poly(ethylene glycol)-modified phosphatidylethanolamine (PEG-PE), can be used as drug carriers
35 for the antibodies of the present invention. The emulsions are composed of two major parts: an oil core, e.g., triglyceride, stabilized by emulsifiers, e.g., phospholipids. The poor emulsifying properties of phospholipids can be enhanced
40 by adding a biocompatible co-emulsifier such as polysorbate 80. In a preferred embodiment, the antibody is conjugated to the surface of the lipid emulsion globules with a poly(ethylene glycol)-based, heterobifunctional coupling agent, poly(ethylene glycol)-vinylsulfone-N-hydroxy-succinimidyl ester (NHS-PEG-VS).

45 The submicron lipid emulsion is prepared and characterized as described.
30 Lundberg, *J. Pharm. Sci.*, 83:72 (1993); Lundberg et al., *Int. J. Pharm.*, 134:119 (1996). The basic composition of the lipid emulsion is triolein:DPPC:polysorbate
50

5 80, 2:1:0.4 (w/w). When indicated, PEG-DPPE is added into the lipid mixture at
an amount of 2-8 mol% calculated on DPPC.

10 The coupling procedure starts with the reaction of the NHS ester group of
NHS-PEG-VS with the amino group of distearoyl phosphatidyl-ethanolamine
15 (DSPE). Twenty-five μ mol of NHS-PEG-VS are reacted with 23 μ mol of DSPE
and 50 μ mol triethylamine in 1 ml of chloroform for 6 hours at 40°C to produce a
poly(ethylene glycol) derivative of phosphatidyl-ethanolamine with a vinylsulfone
20 group at the distal terminus of the poly(ethylene glycol) chain (DSPE-PEG-VS).
For antibody conjugation, DSPE-PEG-VS is included in the lipid emulsion at 2
25 mol% of DPPC. The components are dispersed into vials from stock solutions at
-20°C, the solvent is evaporated to dryness under reduced pressure. Phosphate-
30 buffered saline (PBS) is added, the mixture is heated to 50°C, vortexed for 30
seconds and sonicated with a MSE probe sonicator for 1 minute. Emulsions can be
35 stored at 4°C, and preferably are used for conjugation within 24 hours.

25 15 Coupling of antibodies to emulsion globules is performed via a reaction
between the vinylsulfone group at the distal PEG terminus on the surface of the
globules and free thiol groups on the antibody. Vinylsulfone is an attractive
30 derivative for selective coupling to thiol groups. At approximately neutral pH, VS
will couple with a half life of 15-20 minutes to proteins containing thiol groups.
20 The reactivity of VS is slightly less than that of maleimide, but the VS group is
more stable in water and a stable linkage is produced from reaction with thiol
35 groups.

40 Before conjugation, the antibody is reduced by 50 mM 2-mercaptoethanol for
10 minutes at 4°C in 0.2 M Tris buffer (pH 8.7). The reduced antibody is separated
45 25 from excess 2-mercaptoethanol with a Sephadex G-25 spin column, equilibrated in
50 mM sodium acetate buffered 0.9% saline (pH 5.3). The product is assayed for
protein concentration by measuring its absorbance at 280 nm (and assuming that a 1
mg/ml antibody solution of 1.4) or by quantitation of 125 I-labeled antibody. Thiol
50 30 groups are determined with Aldrichiol™ following the change in absorbance at 343
nm and with cystein as standard.

55 The coupling reaction is performed in HEPES-buffered saline (pH 7.4)
overnight at ambient temperature under argon. Excess vinylsulfone groups are

5 quenched with 2 mM 2-mercaptoethanol for 30 minutes, excess 2-mercaptoethanol
and antibody are removed by gel chromatography on a Sepharose CL-4B column.
The immunoconjugates are collected near the void volume of the column, sterilized
by passage through a 0.45 µm sterile filter, and stored at 4°C.

10 5 Coupling efficiency is calculated using ¹²⁵I-labeled antibody. Recovery of
emulsions is estimated from measurements of [¹⁴C]DPPC in parallel experiments.
The conjugation of reduced LL2 to the VS group of surface-grafted DSPE-PEG-VS
15 is very reproducible with a typical efficiency of near 85%.

10 **7. Therapeutic Use of Antibodies in Simple and Multimodal Regimens**

20 20 The present invention contemplates the use of naked and/or conjugated
antibodies as the primary therapeutic composition for treatment of autoimmune
diseases. Such a composition can contain polyclonal antibodies or monoclonal
antibodies. Preferred antibodies are anti-CD22 antibodies, such as LL2 antibodies,
25 15 including murine LL2 monoclonal antibody, chimeric LL2 antibody, and humanized
LL2 antibody. Antibodies to a single B-cell antigen or to more than one B-cell
antigen may be used. In a preferred embodiment, bispecific antibodies and fusion
30 proteins which comprise specificities for more than one B-cell antigen or epitope are
employed.

20 20 For example, a therapeutic composition of the present invention can contain
a mixture of monoclonal naked anti-CD22 antibodies directed to different, non-
blocking CD22 epitopes. Monoclonal antibody cross-inhibition studies have
35 identified five epitopes on CD22, designated as epitopes A-E. See, for example,
Schwartz-Albiez *et al.*, "The Carbohydrate Moiety of the CD22 Antigen Can Be
40 25 Modulated by Inhibitors of the Glycosylation Pathway," in LEUKOCYTE TYPING
IV. WHITE CELL DIFFERENTIATION ANTIGENS, Knapp *et al.* (eds.), p. 65
(Oxford University Press 1989). As an illustration, the LL2 antibody binds with
epitope B. Stein *et al.*, *Cancer Immunol. Immunother.* 37:293 (1993).
45 30 Accordingly, the present invention contemplates therapeutic compositions
comprising a mixture of monoclonal anti-CD22 antibodies that bind at least two
CD22 epitopes. For example, such a mixture can contain monoclonal antibodies

50

5 that bind with at least two CD22 epitopes selected from the group consisting of epitope A, epitope B, epitope C, epitope D and epitope E.

10 Methods for determining the binding specificity of an anti-CD22 antibody are well-known to those of skill in the art. General methods are provided, for example, by Mole, "Epitope Mapping," in METHODS IN MOLECULAR BIOLOGY, VOLUME 10: IMMUNOCHEMICAL PROTOCOLS, Manson (ed.), pages 105-116 (The Humana Press, Inc. 1992). More specifically, competitive 15 blocking assays to determine CD22 epitope specificity are described by Stein *et al.*, *Cancer Immunol. Immunother.* 37:293 (1993), and by Tedder *et al.*, U.S. patent 10 No. 5,484,892 (1996).

20 The Tedder patent also describes the production of CD22 mutants, which lack one or more immunoglobulin-like domains. These mutant proteins were used to determine that immunoglobulin-like domains 1, 2, 3, and 4 correspond with 25 epitopes A, D, B, and C, respectively. Thus, binding a test antibody with a panel of CD22 proteins lacking particular immunoglobulin-like domain can also identify 15 CD22 epitope specificity.

30 The therapeutic compositions described herein are useful for treatment of autoimmune diseases, particularly for the treatment of Class III autoimmune 35 diseases including immune-mediated thrombocytopenias, such as acute idiopathic 20 thrombocytopenic purpura and chronic idiopathic thrombocytopenic purpura, dermatomyositis, Sydenham's chorea, myasthenia gravis, systemic lupus erythematosus, lupus nephritis, rheumatic fever, polyglandular syndromes, bullous pemphigoid, diabetes mellitus, Henoch-Schonlein purpura, post-streptococcal nephritis, erythema nodosum, Takayasu's arteritis, Addison's disease, rheumatoid 40 arthritis multiple sclerosis, sarcoidosis, ulcerative colitis, erythema multiforme, IgA nephropathy, polyarteritis nodosa, ankylosing spondylitis, Goodpasture's syndrome, 45 thromboangiitis obliterans, Sjogren's syndrome, primary biliary cirrhosis, Hashimoto's thyroiditis, thyrotoxicosis, scleroderma, chronic active hepatitis, polymyositis/dermatomyositis, polychondritis, pemphigus vulgaris, Wegener's 30 granulomatosis, membranous nephropathy, amyotrophic lateral sclerosis, tabes dorsalis, giant cell arteritis/polymyalgia, pernicious anemia, rapidly progressive

50

55

5 glomerulonephritis and fibrosing alveolitis. In this context, the therapeutic compositions are used to deplete the blood of normal B-cells for an extended period.

10 Although naked, preferably anti-CD22, antibodies are the preferred, primary therapeutic compositions for treatment of autoimmune diseases, the efficacy of such naked antibody therapy can be enhanced by supplementing the naked antibodies with other therapies described herein. In such multimodal regimens, the supplemental therapeutic compositions can be administered before, concurrently or after administration of the naked, preferably anti-CD22, antibodies. Multimodal therapy of Class III autoimmune diseases may comprise co-administration of therapeutics 15 that are targeted against T-cells, plasma cells or macrophages, such as antibodies directed against T-cell epitopes, more particularly against the CD4 and CD5 epitopes. Gamma globulins also may be co-administered. In some cases, it may be desirable to co-administer immunosuppressive drugs such as corticosteroids and possibly also cytotoxic drugs. In this case, lower doses of the corticosteroids and 20 cytotoxic drugs can be used as compared to the doses used in conventional therapies, thereby reducing the negative side effects of these therapeutics. The supplemental therapeutic compositions can be administered before, concurrently or after administration of the naked B-cell, preferably anti-CD22, antibodies.

25 In an alternative embodiment, the antibodies to the CD22, CD20, CD19, and CD74 or HLA-DR antigen are conjugated to a drug, toxin, enzyme, hormone, cytokine, immunomodulator, boron compound or therapeutic radioisotope, or a fusion protein of an antibody and a toxin may be used. These conjugates and fusion proteins may be used alone, or in combination with naked B-cell antibodies. In a further preferred embodiment, an antibody is used that comprises an arm that is 30 specific for a low-molecular weight hapten to which a therapeutic agent is conjugated or fused. In this case, the antibody pretargets the B-cells, and the low-molecular weight hapten with the attached therapeutic agent is administered after the antibody has bound to the B-cell targets. Examples of recognizable haptens include, 35 but are not limited to, chelators, such as DTPA, fluorescein isothiocyanate, vitamin B-12 and other moieties to which specific antibodies can be raised.

40 Drugs which are known to act on B-cells, plasma cells and/or T-cells are particularly useful in accordance with the present invention, whether conjugated to a 45

5 B-cell antibody, or administered as a separate component in combination with a naked or conjugated B-cell antibody. These include methotrexate, phenyl butyrate, bryostatin, cyclophosphamide, etoposide, bleomycin, doxorubicin, carmustine, vincristine, procarbazine, dexamethasone, leucovorin, prednisone, maytansinoids
10 such as DM1, calicheamicin, rapamycin, leflunomide, FK506, immuran, fludarabine, azathiopine, mycophenolate, and cyclosporin. Drugs such as immuran, methotrexate, and fludarabine which act on both B-cells and T-cells are particularly preferred. Illustrative of toxins which are suitably employed in accordance with the present invention are ricin, abrin, ribonuclease, DNase I, Staphylococcal
15 enterotoxin-A, pokeweed antiviral protein, gelonin, diphtherin toxin, Pseudomonas exotoxin, Pseudomonas endotoxin and RNases, such as onconase. See, for example, Pastan et al., Cell 47:641 (1986), and Goldenberg, CA - A Cancer Journal for Clinicians 44:43 (1994). Other suitable drugs and toxins are known to those of skill in the art.

20 Cytokine agonists and antagonists may also be used in multimodal therapies according to the present invention. Tumor necrosis factor alpha (TNF α) and interleukin-1 (IL-1) are important in mediating inflammation in rheumatoid arthritis. Accordingly, anti-TNF α reagents, such as Infliximab and Etanercept (Emrel), are useful in multimodal therapy according to the invention, as well as anti-IL-1
25 reagents.

30 Other useful secondary therapeutics useful in multimodal therapies are IL-2 and GM-CSF, which may be conjugated with an anti-B-cell antibody, or combined with a naked anti-B-cell antibody as a separate component.

35 In general, the dosage of administered antibodies will vary depending upon such factors as the patient's age, weight, height, sex, general medical condition and previous medical history. Typically, it is desirable to provide the recipient with a dosage of antibody component, immunoconjugate or fusion protein which is in the range of from about 1 pg/kg to 10 mg/kg (amount of agent/body weight of patient), although a lower or higher dosage also may be administered as circumstances dictate.

40 Administration of antibodies to a patient can be intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, intrapleural, intrathecal, by perfusion
45

50

5 through a regional catheter, or by direct intralesional injection. When administering therapeutic proteins by injection, the administration may be by continuous infusion or by single or multiple boluses. Intravenous injection provides a useful mode of administration due to the thoroughness of the circulation in rapidly distributing
10 5 antibodies.

15 In preferred embodiments, naked anti-B-cell antibodies, particularly anti-CD22 antibodies, are administered at low protein doses, such as 20 milligrams to 2 grams protein per dose, given once, or repeatedly, parenterally. Alternatively,
10 15 naked antibodies are administered in doses of 20 to 1000 milligrams protein per dose, or 20 to 500 milligrams protein per dose, or 20 to 100 milligrams protein per dose.
20

25 The antibodies, alone or conjugated to liposomes, can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the therapeutic proteins are combined in a mixture with a pharmaceutically acceptable carrier. A composition is said to be a "pharmaceutically acceptable carrier" if its administration can be tolerated by a recipient patient. Sterile phosphate-buffered saline is one example of a pharmaceutically acceptable carrier.
30 Other suitable carriers are well-known to those in the art. See, for example, REMINGTON'S PHARMACEUTICAL SCIENCES, 19th Ed. (1995).

35 20 For purposes of therapy, antibodies are administered to a patient in a therapeutically effective amount in a pharmaceutically acceptable carrier. In this regard, a "therapeutically effective amount" is one that is physiologically significant. An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient patient. In the present context, an
40 25 agent is physiologically significant if its presence results in the inactivation or killing of targeted B-cells.

45 Additional pharmaceutical methods may be employed to control the duration of action of an antibody in a therapeutic application. Control release preparations can be prepared through the use of polymers to complex or adsorb the antibody.
30 For example, biocompatible polymers include matrices of poly(ethylene-co-vinyl acetate) and matrices of a polyanhydride copolymer of a stearic acid dimer and sebacic acid. Sherwood *et al.*, *Bio/Technology* 10:1446 (1992). The rate of release
50

5 of an antibody from such a matrix depends upon the molecular weight of the
protein, the amount of antibody within the matrix, and the size of dispersed
particles. Saltzman *et al.*, *Biophys. J.* 55:163 (1989); Sherwood *et al.*, *supra*.
Other solid dosage forms are described in REMINGTON'S PHARMACEUTICAL
10 SCIENCES, 19th ed. (1995).

15 The present invention, thus generally described, will be understood more
readily by reference to the following examples, which are provided by way of
illustration and are not intended to be limiting of the present invention.

10 EXAMPLE 1:

20 Treatment of a patient with humanized LL2

25 A patient undergoes therapy with humanized LL2 monoclonal antibody. The
patient was infused intravenously with 634 mg of humanized LL2 antibody, and the
15 treatment was repeated 6, 13, and 20 days following this initial treatment.
Immediately following the last dose, the serum value of hLL2 was 389.7 $\mu\text{g}/\text{ml}$, and
one month following the last dose the serum value of hLL2 was 186.5 $\mu\text{g}/\text{ml}$.
30 Normal B-cells in the blood prior to therapy with hLL2 were significantly depleted
from the blood 2 months post-therapy, and there was minimal reappearance of
20 normal B cells five months post-therapy. The results are shown in the following
table.

35

40

45

50

55

5

10

15

20

25

30

35

40

45

50

TABLE 1: B-cells and T-cells in blood

Day	T4/T8	% blood B-cells			% blood T-cells	% blood HLA-Dr (Ia)	
		CD19	CD20	Kappa	lambda	CD3	
Flow cytometry							
0	1.5	5	5	6	2	38	6
28		hLL2 therapy					
34		hLL2 therapy					
41		hLL2 therapy					
48		hLL2 therapy					
Flow cytometry							
76	1.3	<2	<2	<1	<1	71	6
191	2.0	<2	<2	<1	<1	73	4

20

55

5

EXAMPLE 2:Treatment of a patient with chronic idiopathic thrombocytopenia purpura

10

A 50-year-old female with chronic idiopathic thrombocytopenia purpura has been treated with prednisone, gamma globulins, and high dose dexamethason, but the disease progresses. She undergoes splenectomy, which fails to stabilize the disease. Her platelet count falls to less than 20,000/microliter, and hemorrhagic events increase in frequency. The patient is then treated with hLL2, 480 mg intravenously each week, for a period of six weeks. Four weeks after the last dose of hLL2, platelet number is increased by 100%, and the hemorrhagic events become infrequent. Three months after the last antibody infusion the disease is in remission.

15

20

EXAMPLE 3:

25

Treatment of a patient with progressive rheumatoid arthritis

30

35

40

A 60-year-old male, with severe progressive rheumatoid arthritis of the finger joints, wrists, and elbows, has failed therapy with methotrexate, and obtains only minor relief when placed on Enbrel therapy. The patient is then treated with hLL2, 600 mg intravenously each week, for a period of eight weeks. After 3 weeks a 30% improvement in measures of disease activity is observed, which is maintained for 6 months. The patient is again treated with hLL2, at the same dose and frequency. The patient continues to improve, and 6 months after the second hLL2 therapy, a 70% improvement is observed. No human anti-hLL2 antibodies are observed at any time during, or after the hLL2 therapy. Although normal B-cells are significantly reduced from the blood, no infectious complications, or other drug-related toxicity are observed.

45

EXAMPLE 4:Treatment of a patient with myasthenia gravis

50

A 55-year-old male has failed all conventional therapy for myasthenia gravis, and is admitted to a neurological intensive therapy unit. The patient was stabilized by plasma

55

5 exchange, and given intravenous immunoglobulin to reduce the titer of anti-acetylcholine receptor antibody. The patient remained bedridden, and was then treated with hLL2, 800 mg intravenously each week, for a period of six weeks. One week after the last dose of
10 hLL2, a 70% drop in B-lymphocytes is observed, and a significant drop in the titer of the anti-acetylcholine was observed. Two months after the last hLL2 dose the patient was mobile, and was released from the hospital.

15 **EXAMPLE 5:**

Combination therapy of progressive rheumatoid arthritis

20 Another patient with severe progressive rheumatoid arthritis of the finger joints, wrists, and elbows, has failed therapy with methotrexate, and obtains only minor relief when placed on Enbrel therapy. The patient is then treated with 300 mg each of hLL2 and Rituximab, intravenously each week, for a period of five weeks. Significant improvement
25 in measures of disease activity is observed, which is maintained for 6 months. The patient is again treated with the same regimen and continues to improve. Six months after the second course of therapy, additional improvement is observed. No human anti-hLL2 or
30 anti-Rituximab antibodies are observed at any time during, or after the therapy. Although normal B-cells are significantly reduced from the blood, no infectious complications, or other drug-related toxicity are observed.

35 **EXAMPLE 6:**

Combination therapy of chronic idiopathic thrombocytopenia purpura

40 A patient with chronic idiopathic thrombocytopenia purpura has been treated with prednisone, gamma globulins, and high dose dexamethason, but the disease progresses. He undergoes splenectomy, which fails to stabilize the disease. The platelet count falls to less
45 than 20,000/microliter, and hemorrhagic events increase in frequency. This patient is treated with 10 mCi of 90-yttrium-hLL2 and 200 mg of hLL2, followed by 300 mg doses each of hLL2 and Rituximab, intravenously each week, for a period of six weeks. Four weeks after the last dose of hLL2 and Rituximab, platelet number is increased by 150%,
50

5 and the hemorrhagic events become infrequent. Three months after the last antibody infusion the disease is in remission.

10 Although the foregoing refers to particular preferred embodiments, it will be understood that the present invention is not so limited. It will occur to those of ordinary skill in the art that various modifications may be made to the disclosed embodiments and that such modifications are intended to be within the scope of the present invention, which is defined by the following claims.

15 All publications and patent applications mentioned in this specification are indicative of the level of skill of those in the art to which the invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application were specifically and individually indicated to 20 be incorporated by reference in its entirety.

25

30

35

40

45

50

55

Claims

5

10

15

20

25

30

35

40

45

50

55

5

What Is Claimed Is:

10

1. A method for treating an autoimmune disorder, comprising administering to a subject having an autoimmune disorder a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one antibody to a B-cell antigen.

15

2. The method of claim 1, wherein said therapeutic composition is administered parenterally in a dosage of from 20 to 2000 mg per dose.

20

3. The method of claim 2, wherein said subject receives said antibody in repeated parenteral dosages.

25

4. The method of claim 1, wherein said antibody is selected from the group consisting of subhuman primate antibody, murine monoclonal antibody, chimeric antibody, humanized antibody, and human antibody.

30

5. The method of claim 4, wherein said antibody is the murine, chimeric, or humanized LL2 antibody.

35

6. The method of claim 1, wherein said therapeutic composition comprises at least two monoclonal antibodies that bind with distinct CD22 epitopes, wherein said CD22 epitopes are selected from the group consisting of epitope A, epitope B, epitope C, epitope D and epitope E.

40

45

50

7. The method of claim 1, wherein said autoimmune disease is selected from the group consisting acute idiopathic thrombocytopenic purpura, chronic idiopathic thrombocytopenic purpura, dermatomyositis, Sydenham's chorea, myasthenia gravis, systemic lupus erythematosus, lupus nephritis, rheumatic fever, polyglandular syndromes, bullous pemphigoid, diabetes mellitus, Henoch-Schonlein purpura, post-streptococcal nephritis, erythema nodosum, Takayasu's arteritis, Addison's disease, rheumatoid arthritis multiple sclerosis, sarcoidosis, ulcerative colitis, erythema multiforme, IgA nephropathy, polyarteritis nodosa, ankylosing spondylitis, Goodpasture's syndrome, thromboangiitis

55

5 ubiterans, Sjogren's syndrome, primary biliary cirrhosis, Hashimoto's thyroiditis,
thyrotoxicosis, scleroderma, chronic active hepatitis, polymyositis/dermatomyositis,
polychondritis, pemphigus vulgaris, Wegener's granulomatosis, membranous nephropathy,
10 amyotrophic lateral sclerosis, tabes dorsalis, giant cell arteritis/polymyalgia, pernicious
anemia, rapidly progressive glomerulonephritis and fibrosing alveolitis.

15 8. The method of claim 1, further comprising separately administering a secondary therapeutic directed against T-cells, plasma cells, or macrophages or inflammatory cytokines.

20 9. The method of claim 8, wherein said secondary therapeutic is administered prior to the administration of said therapeutic composition.

10. The method of claim 9, wherein said secondary therapeutic is administered concurrently with the administration of said therapeutic composition.

11. The method of claim 10, wherein said secondary therapeutic is administered after the administration of said therapeutic composition.

12. The method of claim 1, wherein said B-cell antigen is selected from the group consisting of CD19, CD20, CD22, HLA-DR, and CD74.

13. The method of claim 1, wherein said B-cell antigen is CD22.

14. The method of claim 1, wherein said antibody is a naked antibody.

15. The method of claim 14, wherein said antibody is a naked anti-CD22 antibody.

16. The method of claim 1, further comprising administering a secondary therapeutic directed against T cells, plasma cells, macrophages, or inflammatory mediators.

5 wherein said secondary therapeutic is conjugated to an anti-B-cell antibody or is separately administered.

10 17. The method of claim 1, further comprising administering a secondary therapeutic which is a conjugate of an anti-B-cell antibody with IL-2 or GM-CSF.

15 18. The method of claim 16, wherein said conjugate is used in combination with a naked B-cell antibody.

20 19. The method of claim 1, further comprising administering a secondary therapeutic directed against an inflammatory cytokine.

25 20. The method of claim 19, wherein said secondary therapeutic is an anti-TNF α or anti-IL-1 agent.

30 21. The method of claim 1, comprising administering a naked anti-CD22, anti-CD19, anti-CD20, or anti-CD74 antibody in combination with a conjugate of an anti-CD22, anti-CD19, anti-CD20, or anti-CD74 antibody with a drug, toxin, enzyme, cytokine, hormone, boron compound or therapeutic radionuclide.

35 22. The method of claim 21, wherein said naked antibody and said conjugated antibody are directed against the same antigen or epitope.

40 23. The method of claim 21, wherein said naked antibody and said conjugated antibody are directed against different antigens or epitopes.

45 24. The method of claim 21, wherein said conjugate is a drug conjugate in which the drug is one that acts against B-cells, plasma cells, or T-cells.

25. The method of claim 21, wherein said conjugate is a drug conjugate in which the drug is one that acts against an inflammatory cytokine.

50

55

5 26. The method of claim 21, wherein said conjugate comprises an enzyme.

27. The method of claim 26, wherein said enzyme is an RNase.

10 28. The method of claim 1, wherein said therapeutic composition comprises a hybrid antibody which binds more than one B-cell antigen.

15 29. The method of claim 1, wherein said therapeutic composition comprises a hybrid antibody which binds more than one epitope of the same B-cell antigen.

20 30. The method of claim 1, wherein said therapeutic composition comprises a bispecific fusion protein, in which at least one arm targets a B-cell and a second arm targets a T-cell, plasma cell or macrophage antigen.

25 31. The method of claim 1, comprising administering a conjugate of an anti-CD19, anti-CD20, anti-CD22 or anti-CD74 antibody with a drug, toxin, enzyme, cytokine, hormone, boron compound or therapeutic radionuclide.

30 32. The method of claim 16, wherein said drug is selected from the group consisting of methotrexate, phenyl butyrate, bryostatin, cyclophosphamide, etoposide, bleomycin, doxorubicin, carmustine, vincristine, procarbazine, dexamethasone, leucovorin, 35 prednisone, maytansinoids such as DM1, calicheamicin, rapamycin, leflunomide, FK506, immurana, fludarabine, azathioprine, mycophenolate, and cyclosporine.

40 33. The method of claim 16, wherein said drug is selected from the group consisting of immurana, methotrexate, and fludarabine.

45 34. The method of claim 1, wherein said antibody comprises an arm that is specific for a low-molecular weight hapten and wherein a low-molecular weight hapten with an attached therapeutic agent is administered after the antibody has bound to the B-cell antigen.

50

5 35. The method of claim 34, wherein said hapten is a chelator.

10 36. The method of claim 17, wherein said conjugate is used in combination with
a naked B-cell antibody.

15 37. A therapeutic composition comprising a pharmaceutically acceptable carrier
and at least one antibody to a B-cell antigen for use to treat an autoimmune disorder.

20 38. The use according to claim 37, wherein said therapeutic composition is in the
form of dosage units of from 20 to 2000 mg per dose, for parenteral administration.

25 39. The use according to claim 37, comprising a plurality of said parenteral doses
for repeated parenteral administration.

30 40. The use according to claim 37, wherein said antibody is selected from the group
consisting of subhuman primate antibody, murine monoclonal antibody, chimeric antibody,
humanized antibody, and human antibody.

35 41. The use according to claim 40, wherein said antibody is the murine, chimeric,
or humanized LL2 antibody.

40 42. The use according to claim 37, wherein said therapeutic composition comprises
at least two monoclonal antibodies that bind with distinct CD22 epitopes, wherein said CD22
epitopes are selected from the group consisting of epitope A, epitope B, epitope C, epitope D
and epitope E.

45 43. The use according to claim 37, wherein said autoimmune disease is selected
from the group consisting acute idiopathic thrombocytopenic purpura, chronic idiopathic
thrombocytopenic purpura, dermatomyositis, Sydenham's chorea, myasthenia gravis,
systemic lupus erythematosus, lupus nephritis, rheumatic fever, polyglandular syndromes,
bullous pemphigoid, diabetes mellitus, Henoch-Schonlein purpura, post-streptococcal
50 nephritis, erythema nodosum, Takayasu's arteritis, Addison's disease, rheumatoid arthritis

5 multiple sclerosis, sarcoidosis, ulcerative colitis, erythema multiforme, IgA nephropathy, polyarteritis nodosa, ankylosing spondylitis, Goodpasture's syndrome, thromboangiitis obliterans, Sjogren's syndrome, primary biliary cirrhosis, Hashimoto's thyroiditis, thyrotoxicosis, scleroderma, chronic active hepatitis, polymyositis/dermatomyositis, 10 polychondritis, pemphigus vulgaris, Wegener's granulomatosis, membranous nephropathy, amyotrophic lateral sclerosis, tabes dorsalis, giant cell arteritis/polymyalgia, pernicious anemia, rapidly progressive glomerulonephritis and fibrosing alveolitis.

15

44. The use according to claim 37, further comprising a secondary therapeutic directed against T-cells, plasma cells, or macrophages or inflammatory cytokines which is separately administered.

20

45. The use according to claim 44, wherein said secondary therapeutic is administered prior to the administration of said therapeutic composition.

25

46. The use according to claim 45, wherein said secondary therapeutic is administered concurrently with the administration of said therapeutic composition.

30

47. The use according to claim 46, wherein said secondary therapeutic is administered after the administration of said therapeutic composition.

35

48. The use according to claim 37, wherein said B-cell antigen is selected from the group consisting of CD19, CD20, CD22, HLA-DR and CD74.

40

49. The use according to claim 37, wherein said B-cell antigen is CD22.

50. The use according to claim 37, wherein said antibody is a naked antibody.

45

51. The use according to claim 50, wherein said antibody is a naked anti-CD22 antibody.

50

55

5 52. The use according to claim 37, further comprising a secondary therapeutic directed against T-cells, plasma cells, macrophages, or inflammatory cytokines, wherein said secondary therapeutic is conjugated to an anti-B-cell antibody or is separately administered.

10

15 53. The use according to claim 37, further comprising a secondary therapeutic which is a conjugate of an anti-B-cell antibody with IL-2 or GM-CSF.

15

54. The use according to claim 52, wherein said conjugate is used in combination with a naked B-cell antibody.

20

55. The use according to claim 37, further comprising a secondary therapeutic directed against an inflammatory cytokine.

25

56. The use according to claim 55, wherein said secondary therapeutic is an anti-TNF α or anti-IL-1 agent.

30

57. The use according to claim 37, wherein said therapeutic composition comprises a combination of (i) a naked anti-CD22, anti-CD19, anti-CD20, or anti-CD74 antibody, and (ii) a conjugate of an anti-CD22, anti-CD19, anti-CD20, or anti-CD74 antibody with a drug, toxin, enzyme, cytokine, hormone, boron compound or therapeutic radionuclide.

35

40

58. The use according to claim 57, wherein said naked antibody and said conjugated antibody are directed against the same antigen or epitope.

45

59. The use according to claim 57, wherein said naked antibody and said conjugated antibody are directed against different antigens or epitopes.

50

60. The use according to claim 57, wherein said conjugate is a drug conjugate in which the drug is one that acts against B-cells, plasma cells, or T-cells.

55

5 61. The use according to claim 57, wherein said conjugate is a drug conjugate in which the drug is one that acts against an inflammatory cytokine.

10 62. The use according to claim 57, wherein said conjugate comprises an enzyme.

15 63. The use according to claim 62, wherein said enzyme is an RNase.

20 64. The use according to claim 37, wherein said therapeutic composition comprises a hybrid antibody which binds more than one B-cell antigen.

25 65. The use according to claim 37, wherein said therapeutic composition comprises a hybrid antibody which binds more than one epitope of the same B-cell antigen.

30 66. The use according to claim 37, wherein said therapeutic composition comprises a bispecific fusion protein, in which at least one arm targets a B-cell and a second arm targets a T-cell, plasma cell or macrophage antigen.

35 67. The use according to claim 37, wherein said therapeutic composition is a conjugate of an anti-CD19, anti-CD20, anti-CD22 or anti-CD74 antibody with a drug, toxin, enzyme, cytokine, hormone, boron compound or therapeutic radionuclide.

40 68. The use according to claim 52, wherein said drug is selected from the group consisting of methotrexate, phenyl butyrate, bryostatin, cyclophosphamide, etoposide, bleomycin, doxorubicin, carmustine, vincristine, procarbazine, dexamethasone, leucovorin, prednisone, maytansinoids such as DM1, calicheamicin, rapamycin, leflunomide, FK506, immuran, fludarabine, azathioprine, mycophenolate, and cyclosporin.

45 69. The use according to claim 52, wherein said drug is selected from the group consisting of immuran, methotrexate, and fludarabine.

50 70. The use according to claim 37, wherein said antibody comprises an arm that is specific for a low-molecular weight hapten and wherein a low-molecular weight hapten

5 with an attached therapeutic agent is administered after the antibody has bound to the B-cell antigen.

10 71. The use according to claim 70, wherein said hapten is a chelator.

15 72. The use according to claim 53, wherein said conjugate is used in combination with a naked B-cell antibody.

20

25

30

35

40

45

50

55

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 00/15780

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K39/395 C07K16/28 C07K19/00 A61P37/06 //C07K14/55		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, WPI Data, PAJ, MEDLINE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	
X	WO 91 13974 A (PESANDO JOHN M ;BIOMEMBRANE INST (US)) 19 September 1991 (1991-09-19)	1-4, 7-12,16, 18, 31-33, 37-40, 43-48, 50,52, 54,67-69 17,19, 20,25, 28-30, 36,53, 55,56, 61, 64-66,72
Y	abstract page 1, line 21-35 page 4, line 3 - line 33 page 5, line 8-15 page 7, line 1 - line 17	-/-
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.
<p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
Date of the actual completion of the international search	Date of mailing of the international search report	
2 November 2000	13.11.00	
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patenttaan 2 NL - 2290 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 cpo nl. Fax: (+31-70) 340-3016	Authorized officer Montrone, M	

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 00/15780

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	page 8, line 31 - line 37 page 9, line 4 - line 28 WO 94 27638 A (DANA FARBER CANCER INST INC) 8 December 1994 (1994-12-08)	1-4, 7, 12-15, 37-40, 43, 48-51
Y	abstract page 3, line 18 - line 33 page 4, line 13 -page 5, line 28 page 9, line 15 - line 30 page 10, line 1 - line 35 page 11, line 6-18 page 11, line 19 -page 12, line 7	5, 6, 22, 26-30, 34, 35, 41, 42, 58, 62-66, 70, 71
X	US 5 686 072 A (SCHEUERMANN RICHARD H ET AL) 11 November 1997 (1997-11-11)	1-4, 7-16, 18, 21, 23, 24, 31, 37-40, 43-52, 54, 57, 59, 60, 67
Y	abstract column 1, line 16-61 column 2, line 43-54 column 4, line 19-64 column 5, line 1-6 column 6, line 16-50 column 12, line 18-31	5, 6, 22, 26, 27, 41, 42, 58, 62, 63
X	ROWAN W ET AL: "Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells." IMMUNOLOGY, vol. 95, no. 3, November 1998 (1998-11), pages 427-436, XP000942636 ISSN: 0019-2805 abstract page 434, column 2, paragraph 4 -page 435, column 1, line 2	1-4, 37-40
		-/-

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 00/15780

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LEVINE TODD D ET AL: "IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab." NEUROLOGY, vol. 52, no. 8, 12 May 1999 (1999-05-12), pages 1701-1704, XP000942610 ISSN: 0028-3878 abstract page 1702, column 2, paragraph 2	1-4, 7, 12, 37-40, 43, 48
X	THEOCHARIS STAMATIOS ET AL: "Characterization of in vivo mutated T cell clones from patients with systemic lupus erythematosus." CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 74, no. 2, 1995, pages 135-142, XP000942609 ISSN: 0090-1229 abstract page 135, column 1, line 1-4 page 139, column 1, paragraph 1 -column 2, paragraph 2 page 140, column 2, paragraph 3 -page 141, column 1, paragraph 1	1, 7, 12, 37, 43, 48
Y	US 5 795 967 A (AGGARWAL BHARAT B ET AL) 18 August 1998 (1998-08-18)	17, 19, 20, 25, 36, 53, 55, 56, 61, 72
Y	abstract column 1, line 23-29 column 4, line 40-55	
Y	QU ZHENGXING ET AL: "Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates." JOURNAL OF IMMUNOLOGICAL METHODS, vol. 213, no. 2, 15 April 1998 (1998-04-15), pages 131-144, XP002103672 ISSN: 0022-1759 abstract	34, 35, 70, 71
Y	STEIN RHONA ET AL: "Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2." CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 37, no. 5, 1993, pages 293-298, XP002070322 ISSN: 0340-7004 abstract page 293, column 2, paragraph 2	5, 41
	---	-/-

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 00/15780

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>WO 99 54440 A (RIETHMUELLER GERT ;BARGOU RALF (DE); DOERKEN BERND (DE); KUFER PET) 28 October 1999 (1999-10-28)</p> <p>abstract page 11, paragraph 3 -page 12, paragraph 3 page 23, paragraph 3 claims 24,30</p> <p>---</p> <p>PROTHEROE A ET AL: "Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma." RHEUMATOLOGY (OXFORD), vol. 38, no. 11, November 1999 (1999-11), pages 1150-1152, XP000942661 ISSN: 1462-0324</p> <p>abstract page 1150, column 2, paragraph 2 page 1151, column 2, paragraph 3</p> <p>---</p>	<p>1-4,7, 12, 30-32, 37-40, 43,48, 50,66-68</p> <p>1-4, 7-12,16, 18, 31-33, 37-40, 43-48, 50,52, 54,67-69</p>
1		

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/US 00/15780**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-36 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No	
PCT/US 00/15780	

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9113974	A	19-09-1991	AU	7566991 A	10-10-1991
WO 9427638	A	08-12-1994	US	5484892 A	16-01-1996
			CA	2140538 A	08-12-1994
			EP	0660721 A	05-07-1995
US 5686072	A	11-11-1997		NONE	
US 5795967	A	18-08-1998	US	5672347 A	30-09-1997
			MX	9203709 A	01-09-1992
			AT	113295 T	15-11-1994
			AU	599571 B	26-07-1990
			AU	4465285 A	09-01-1986
			BG	60250 B	24-03-1994
			CZ	8505067 A	16-07-1997
			DE	3587939 D	01-12-1994
			DE	3587939 T	27-04-1995
			DK	75694 A	24-06-1994
			DK	305885 A	14-03-1986
			EP	0168214 A	15-01-1986
			FI	852626 A,B	06-01-1986
			FI	943750 A,B	15-08-1994
			GR	851626 A	26-11-1985
			HR	950156 A	31-08-1997
			HU	209153 B	28-03-1994
			IE	65426 B	01-11-1995
			IL	75717 A	28-11-1994
			IL	105271 A	31-07-1995
			JP	7291997 A	07-11-1995
			JP	2614989 B	28-05-1997
			JP	8003061 A	09-01-1996
			JP	2557341 B	27-11-1996
			JP	61040221 A	26-02-1986
			JP	9028387 A	04-02-1997
			KR	9310767 B	10-11-1993
			LU	90456 A	06-12-1999
			NO	852673 A	06-01-1986
			NZ	212632 A	28-05-1991
			PL	254399 A	17-06-1986
			PT	80758 A,B	01-08-1985
			SI	8511132 A,B	31-10-1996
			SK	506785 A	07-05-1999
			YU	113285 A	30-04-1991
			ES	544843 D	01-05-1988
			ES	8802250 A	01-07-1988
			ES	557105 D	16-12-1987
			ES	8800984 A	16-02-1988
WO 9954440	A	28-10-1999	AU	4135299 A	08-11-1999